Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
1.030
0.00 (0.00%)
Apr 13, 2026, 12:39 PM EDT - Market open
Biofrontera Revenue
In the year 2025, Biofrontera had annual revenue of $41.71M with 11.75% growth. Biofrontera had revenue of $17.10M in the quarter ending December 31, 2025, with 36.16% growth.
Revenue (ttm)
$41.71M
Revenue Growth
+11.75%
P/S Ratio
0.29
Revenue / Employee
$443,670
Employees
94
Market Cap
12.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.71M | 4.38M | 11.75% |
| Dec 31, 2024 | 37.32M | 3.25M | 9.54% |
| Dec 31, 2023 | 34.07M | 5.40M | 18.82% |
| Dec 31, 2022 | 28.67M | 4.57M | 18.98% |
| Dec 31, 2021 | 24.10M | 5.25M | 27.86% |
| Dec 31, 2020 | 18.85M | -7.33M | -28.01% |
| Dec 31, 2019 | 26.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rockwell Medical | 69.26M |
| Aytu BioPharma | 62.64M |
| Sunshine Biopharma | 36.31M |
| cbdMD | 19.09M |
| RedHill Biopharma | 9.55M |
| China Pharma Holdings | 4.14M |
| TherapeuticsMD | 3.02M |
| BioXcel Therapeutics | 642.00K |
BFRI News
- 25 days ago - Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update - GlobeNewsWire
- 4 weeks ago - Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026 - GlobeNewsWire
- 5 weeks ago - Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris - GlobeNewsWire
- 6 weeks ago - U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable - GlobeNewsWire
- 7 weeks ago - Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities - GlobeNewsWire
- 2 months ago - Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma - GlobeNewsWire
- 2 months ago - Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint - GlobeNewsWire
- 3 months ago - Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth - GlobeNewsWire